Taking a “set it and forget it” approach to retirement planning works in some areas, such as setting up automatic contributions to retirement savings so you don’t even have to think about it. But in other areas, it’s not the right approach. One of those areas has to do with actively “stress testing” your retirement plan to identify weak points and make adjustments as needed, according to Rob Williams, head of financial planning and wealth management research at Charles Schwab. “Even when your retirement ...

NatWest Group has agreed to purchase UK wealth manager Evelyn Partners from Permira and Warburg Pincus-advised funds in a deal valued at £2.7bn ($3.6bn). The combined business will oversee £127bn in assets under management and administration. Evelyn Partners manages £69bn in client assets. Its operations include financial planning, discretionary investment management, and the consumer platform BestInvest. Permira first invested in Bestinvest in 2014, and Warburg Pincus has been a minority investor sin ...

Ciena (CIEN) shares ended the last trading session 7.2% higher at $271.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks.The increase in share price can be attributed to increased network traffic, demand for bandwidth and the adoption of cloud architecture. Ciena is set to join the S&P 500. The index news is hitting at a time when sentiment on optical networking is already impr ...

If you're contributing money to a 401(k) plan on a regular basis, you're doing your part to set yourself up for a secure retirement. Social Security might only replace 40% of your pre-retirement paycheck if you earn an average wage. But living on 60% less income could be challenging, even at a time when your expenses might be lower. So it's important to have savings to supplement those benefits. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy ...

Core Viewpoint - Novo Nordisk has initiated legal action against U.S. telehealth company Hims & Hers, alleging patent infringement [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company known for its focus on diabetes care and other chronic conditions [1] - Hims & Hers is a telehealth company based in the U.S. that provides various health services, including prescription medications [1]

The recent silver correction might have been the largest in history, yet it has not done much to reduce the interest in the metal. Instead of forcing traders out of their positions, demand for physical metal appears to remain intact.However, the tension between the paper and physical market has to be resolved. Open interest declined from roughly 110,000 contracts in early December to about 76,000 in March. Still, that level is historically large enough to cause problems if too many holders demand physical d ...

Core Viewpoint - Apollo Global Management reported a decline in fourth-quarter profit due to increased tax provisions and losses from investment activities, despite strong revenue growth and higher quarterly inflows [1] Financial Performance - The company's profit fell in the fourth quarter, primarily driven by a higher tax provision and losses from investment activities [1] - Revenue gains were strong, indicating positive operational performance, but were overshadowed by the aforementioned factors [1] - Quarterly inflows increased, suggesting a robust interest in the company's investment offerings [1]

Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday. ...

Core Insights - Kyndryl reported revenues of $3.9 billion for the third quarter of fiscal year 2026, reflecting a 3% year-over-year increase on a reported basis, while remaining unchanged in constant currency [3][6] - The company experienced a decline in pretax income to $91 million from $258 million in the prior-year period, primarily due to a significant transaction-related benefit recorded last year [3][4] - Kyndryl's net income was $57 million, or $0.25 per diluted share, compared to $215 million, or $0.89 per diluted share, in the same quarter last year [3][4] Financial Performance - Adjusted pretax income increased to $168 million, up $8 million from $160 million in the prior-year period, driven by contributions from Kyndryl's three-A initiatives [4][10] - Adjusted net income was $122 million, or $0.52 per diluted share, compared to $124 million, or $0.51 per diluted share, in the prior-year period [4][10] - Cash flow from operations was $427 million, significantly higher than $260 million in the prior-year period [3][21] Business Segments and Growth - Kyndryl Consult achieved double-digit revenue growth of 24% year-over-year in the third quarter, with total revenues of $3.6 billion over the last twelve months [7][10] - The company signed eleven customer contracts exceeding $50 million each during the third quarter, contributing to total signings of $15.4 billion for the trailing twelve months [4][10] - Revenue from hyperscaler alliances reached $500 million, marking a 58% year-over-year increase, and is expected to exceed the initial target of $1.8 billion for fiscal 2026 [7][10] Strategic Initiatives - Kyndryl continues to expand its AI-related capabilities, with a quarter of its signings now including AI-related content [10] - The company announced the acquisition of Solvinity Group, B.V., a provider of secure managed cloud platforms and services, expected to close in the first half of calendar year 2026 [10] - Leadership changes were made, with Harsh Chugh appointed as Interim Chief Financial Officer and other key positions filled [7][10] Fiscal Year 2026 Outlook - Kyndryl provided an outlook for fiscal year 2026, projecting adjusted pretax income of $575 to $600 million and free cash flow of $325 to $375 million [10][10] - The company anticipates a constant-currency revenue decline of 2% to 3% for the fiscal year [10]

Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]